SSY Group Wins NMPA Approvals for Methocarbamol Tablets and Phloroglucinol Bulk Drug
I'm LongbridgeAI, I can summarize articles.SSY Group (HK:2005) secured NMPA approvals for Methocarbamol Tablets and Phloroglucinol Dihydrate bulk drug, becoming the first in mainland China to register the former. These regulatory clearances expand its pain-management portfolio and reinforce its position in China's generic medicine market. The company also received prior approval for Phloroglucinol Injection. Analysts maintain a 'Buy' rating with a HK$5.00 price target.
SSY Group ( (HK:2005) ) has shared an update.
SSY Group has become the first entity in mainland China to secure National Medical Products Administration approval for the production and registration of 0.5g Methocarbamol Tablets, a muscle relaxant used to treat joint and muscle sprains, lumbar muscle strain and sciatica. The drug’s consistency evaluation status underscores the group’s capability to meet stringent regulatory standards in the competitive generic medicines market.
The company also obtained NMPA registration approval for Phloroglucinol Dihydrate as a bulk drug, following its earlier clearance for Phloroglucinol Injection, enabling broader use in preparations targeting acute spasmodic pain in digestive, urinary and gynecological systems. These approvals expand SSY Group’s pain-management portfolio and signal continued progress in product development, which may enhance its positioning in China’s hospital and prescription drug segments.
The most recent analyst rating on (HK:2005) stock is a Buy
with a HK$5.00 price target.
To see the full list of analyst forecasts on SSY Group stock,
see the HK:2005 Stock Forecast page.
More about SSY Group
SSY Group Limited is a pharmaceutical company based in China, focusing on the development, production and registration of chemical drugs for the domestic healthcare market. The group’s portfolio includes muscle relaxants and treatments for pain related to digestive, urinary and gynecological conditions, reflecting a strategy centered on specialty therapeutics approved by Chinese regulators.
Average Trading Volume: 5,939,423
Technical Sentiment Signal: Sell
Current Market Cap: HK$6.26B
Find detailed analytics on 2005 stock on TipRanks’ Stock Analysis page.